GLP-1 Receptor Agonist Use and Risk of Suicide Death.

ABSTRACT:

Importance

Concerns have been raised regarding a link between use of glucagon-like peptide-1 (GLP-1) receptor agonists and increased risk of suicidality and self-harm.

Objective

To assess the association between use of GLP-1 receptor agonists and the risk of suicide death in routine clinical practice.

Design, setting, and participants

This active-comparator new-user cohort study used nationwide register data from Sweden and Denmark from 2013 to 2021. Adults 18 to 84 years old who initiated treatment with GLP-1 receptor agonists or the comparator sodium-glucose cotransporter-2 (SGLT2) inhibitors were included. Data were analyzed from March to June 2024.

Exposure

Initiation of treatment with a GLP-1 receptor agonist or SGLT2 inhibitor.

Main outcomes and measur

SUBMITTER: Ueda P 

PROVIDER: S-EPMC11372654 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature